Mirikizumab is a first-in-class monoclonal antibody that targets the p19 subunit of interleukin-23. It is approved for moderate-to-severe active ulcerative colitis and, as of January 2025, Crohn's disease in adults, giving clinicians a newer option across the inflammatory bowel disease…
Ustekinumab is a widely used monoclonal antibody. It is effective at inducing and maintaining remission across several inflammatory diseases, yet a meaningful share of patients still lose response over time. Real-world and long-term data suggest that roughly half of patients…
Adalimumab (ADM) is one of the most widely prescribed biologics in inflammatory disease, yet a substantial share of patients fail to reach or sustain remission. Up to half of patients on anti-TNF therapy experience secondary loss of response, and much…
The TITRATE study enrolled 25 patients on standard IFX dosing (5 mg/kg at weeks 0, 2, and 6) and 23 patients on personalised IFX dosing using iDose. Precision dosing in patients with acute severe ulcerative colitis guided by iDose's Bayesian…
Biologic therapies have transformed the treatment of inflammatory bowel disease (IBD). Yet despite these advances, many patients still lose response to therapy over time or never respond at all. Therapeutic drug monitoring (TDM) has emerged as a powerful tool to…
When it comes to managing inflammatory bowel disease (IBD) with infliximab (IFX), the traditional approach of standard dosing leaves many patients behind. A groundbreaking 2020 study from Mumbai's P.D. Hinduja Hospital demonstrates how Baysient's iDose software is changing that reality…
In March 2025, a federal district court issued a landmark ruling that reaffirmed a critical distinction in healthcare regulation: clinical laboratory services are not medical devices. The ruling struck down the FDA’s attempt to expand its authority over lab-developed tests…
Pediatric inflammatory bowel disease (IBD) is no longer rare, and it’s no longer acceptable to treat it with outdated tools and timelines. Pediatric IBD accounts for approximately 25% of all newly diagnosed IBD patients. Clinical experience confirms that although the…
Despite significant advancements in biologic therapy for pediatric inflammatory bowel disease (IBD), loss of response (LOR) remains a major challenge in clinical management. Infliximab (IFX) and Vedolizumab (VEDO), both widely used monoclonal antibodies, offer disease-modifying benefits, yet many pediatric patients…
Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like infliximab, has long been challenged by issues such as antibody formation, variable drug clearance, and the high costs associated with frequent dosing. In many cases, biologics are introduced only in…
